Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

Biotechnology

Healthcare
$1.72 -2.64%

-$0.05 today

Market cap
$765.80M
Beta
1.07
P/E (TTM)
-30.5
EPS (TTM)
-$0.07
52W Low $0.71High $2.53

Volume 2.02M

Average 2.48M

LXRX Pre-Tax Margin

Income before tax as a percentage of revenue.

Lexicon Pharmaceuticals, Inc.NASDAQ: LXRX

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to -4.9%

Pre-tax margin was -4.9% in Q1 FY2026, up 1999.4 pp from a year earlier. On a trailing-twelve-month basis it was -37.5%, up 530.6 pp year over year. Over 3 fiscal years it widened by 73239.9 pp.

Context

  • Pre-tax margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-4.9%+277.8 pp QoQ
Last fiscal yearDec 2025
-101.1%+543.7 pp YoY
LTMMar 2026
-37.5%+530.6 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1999.4 pp——
1 year+543.7 pp——
3 years+73239.9 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-101.1%
Year-over-year change
+543.7pp

Pre-Tax Margin vs competitors

How LXRX compares with its peers on the latest reported figures

  • LXRX's LTM Mar 2026 pre-tax margin of -37.5% is the 4th highest of the 7 companies compared; the peer median is -24.2%.
  • Its year-over-year change of +530.6 pp is the 2nd highest of 7, against a peer median of -24.5 pp.
  • Over three fiscal years its change of +73239.9 pp compares with a peer median of +105.5 pp.
LXRX Competitors Peer median
Pre-Tax Margin for LXRX and competitors
Company Period LTM level YoY 3-year change
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202640.7% +21.9 pp+90.1 pp
PTCTPTC Therapeutics, Inc.LTM Jun 2026-6.6% -44.4 pp+124.3 pp
MNKDMannKind CorporationLTM Mar 2026-7.9% -19.1 pp+88.0 pp
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026-37.5% +530.6 pp+73239.9 pp
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026-40.5% -34.8 pp+120.8 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-56.7% -29.9 pp+3.7 pp
OVIDOvid Therapeutics Inc.LTM Mar 2026-339.3% +4217.8 pp+3364.5 pp
TRVITrevi Therapeutics, Inc.FY2025— ——
ORICORIC Pharmaceuticals, Inc.FY2025— ——
DMACDiaMedica Therapeutics Inc.FY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding LXRX) -24.2%-24.5 pp+105.5 pp

Competitors are the stored peer set for LXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue298K139K1.2M31.08M49.8M
Cost of Revenue55.05M52.52M58.97M616K274K
Gross Profit(54.75M)(52.38M)(57.77M)30.47M49.53M
Gross Margin-18371.8%-37681.3%-4798.0%98.0%99.4%
Research & Development55.05M52.82M58.89M84.48M61.12M
Selling, General & Admin000131.9M37.32M
Operating Expenses32.34M48.38M113.98M227.58M98.44M
Depreciation & Amortization292K427K554K534K621K
EBITDA(86.66M)(100.03M)(169.76M)(184.29M)(41.38M)
EBITDA Margin-29081.9%-71966.2%-14099.3%-592.9%-83.1%
Operating Income(87.09M)(100.76M)(171.75M)(197.12M)(48.91M)
Operating Margin-29224.8%-72489.2%-14265.0%-634.2%-98.2%
Interest Income134K1.6M7.73M12.29M6.91M
Interest Expense802K2.78M13.1M15.58M8.34M
Other Income / Expenses(668K)(1.18M)(5.37M)(3.29M)(1.43M)
Income Before Tax(87.76M)(101.94M)(177.12M)(200.4M)(50.34M)
Pre-Tax Margin-29449.0%-73341.0%-14710.9%-644.8%-101.1%
Income Tax Expense00000
Net Income(87.76M)(101.94M)(177.12M)(200.4M)(50.34M)
Net Margin-29449.0%-73341.0%-14710.9%-644.8%-101.1%
EPS (Basic)(0.61)(0.62)(0.80)(0.63)(0.14)
EPS (Diluted)(0.61)(0.62)(0.80)(0.63)(0.14)
Weighted Avg Shares145.65M165.73M221.13M320.03M363.05M
Weighted Avg Shares (Diluted)145.65M165.73M221.13M320.03M363.05M

Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

Intrinsic Alpha fair value

Locked

Current Price

$1.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.